<헤모위클리 5월 1주>

"따뜻한 5월 맞이하세요"

혈우전문지 헤모필리아라이프에서 보내드리는 주간 ‘헤모뉴스 스크랩’입니다. (수신 신청 : 010-3589-2694 / 현재 수신 745명)

■ 피하주사 '헴리브라', 오늘부터 혈우병A 전체에 건보 적용

https://bit.ly/44nBbDJ

■ CSL 베링코리아, B형 혈우병 치료제 ‘아이델비온’ 21일 간격 투여 식약처 허가

https://bit.ly/3p5hBvu

■ 미도리 시마 교수 "혈우병 치료의 변화, 환자가 적극 이용해야"

https://bit.ly/3LNp2jS

■ 박원숙 원장 "치료제 뿐 아니라 혈우병 환자의 자존감 중요"

https://bit.ly/3VmFACu

■ "진짜 예방이 되는 예방요법을 찾았어요"

https://bit.ly/3AIaege

■ 한국화이자, 2023년 하계 인턴십 모집

https://bit.ly/3LJFeTu

■ 컨시주맙, 캐나다에서 혈우병B 항체 치료제로 승인

https://bit.ly/3NqcqAE

■ Belief BioMed, 유전자 치료제 후보물질 임상 3상 투여 완료

https://bit.ly/44kR8dx

■ 결혼, 장애, 지병, 그리고 사랑에 대한 생각

https://bit.ly/42cA6ws

■ WFH 인도주의적 지원 프로그램 2022 영향 보고서 발표

https://bit.ly/3HxcuuG

■ [인터뷰] "혈우병 환자에 있어 신체활동은 필수"

https://www.yakup.com/news/index.html?mode=view&cat=12...

■ 혈우병은 희귀질환계의 당뇨병… "관리하면 오래 살아"

https://bit.ly/42hGJxo

■ GC녹십자 "혈우병 인식 개선코자"…건물에 영상 띄웠다

https://bit.ly/42dmPE2